CH519847A - Mittel zur Steigerung der Lerngeschwindigkeit und zur Verlängerung der Beibehaltung des erlernten Verhaltens bei Tieren - Google Patents
Mittel zur Steigerung der Lerngeschwindigkeit und zur Verlängerung der Beibehaltung des erlernten Verhaltens bei TierenInfo
- Publication number
- CH519847A CH519847A CH200167A CH200167A CH519847A CH 519847 A CH519847 A CH 519847A CH 200167 A CH200167 A CH 200167A CH 200167 A CH200167 A CH 200167A CH 519847 A CH519847 A CH 519847A
- Authority
- CH
- Switzerland
- Prior art keywords
- sep
- phenyl
- imino
- oxazolidin
- base
- Prior art date
Links
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 title claims description 38
- 239000003814 drug Substances 0.000 title abstract description 8
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims abstract description 22
- 239000000347 magnesium hydroxide Substances 0.000 claims abstract description 22
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims abstract description 22
- 230000014759 maintenance of location Effects 0.000 claims abstract description 17
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 12
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims abstract description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 7
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract description 6
- 239000001095 magnesium carbonate Substances 0.000 claims abstract description 6
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 230000006399 behavior Effects 0.000 claims description 16
- 241000700159 Rattus Species 0.000 claims description 10
- 229920002261 Corn starch Polymers 0.000 claims description 8
- 239000008120 corn starch Substances 0.000 claims description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
- 239000008101 lactose Substances 0.000 claims description 6
- 230000004936 stimulating effect Effects 0.000 claims description 5
- 230000001419 dependent effect Effects 0.000 claims description 4
- 235000019359 magnesium stearate Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000454 talc Substances 0.000 claims description 4
- 229910052623 talc Inorganic materials 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 230000007062 hydrolysis Effects 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 7
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract description 2
- 150000001342 alkaline earth metals Chemical class 0.000 abstract description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 abstract description 2
- 239000000920 calcium hydroxide Substances 0.000 abstract description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 abstract description 2
- 229910021502 aluminium hydroxide Inorganic materials 0.000 abstract 1
- 235000010216 calcium carbonate Nutrition 0.000 abstract 1
- 235000011116 calcium hydroxide Nutrition 0.000 abstract 1
- 229910001679 gibbsite Inorganic materials 0.000 abstract 1
- 235000014380 magnesium carbonate Nutrition 0.000 abstract 1
- 235000012254 magnesium hydroxide Nutrition 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 7
- 241000282472 Canis lupus familiaris Species 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004886 head movement Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 229910052790 beryllium Inorganic materials 0.000 description 1
- ATBAMAFKBVZNFJ-UHFFFAOYSA-N beryllium atom Chemical compound [Be] ATBAMAFKBVZNFJ-UHFFFAOYSA-N 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- -1 elixirs Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- TWXDDNPPQUTEOV-UHFFFAOYSA-N hydron;n-methyl-1-phenylpropan-2-amine;chloride Chemical compound Cl.CNC(C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US526345A US3348999A (en) | 1966-02-10 | 1966-02-10 | Compositions to enhance the learning rate and retention level in animals comprising 2-imino-5-phenyl-4-oxazolidinone and a relatively insoluble base |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH519847A true CH519847A (de) | 1972-03-15 |
Family
ID=24096955
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH200167A CH519847A (de) | 1966-02-10 | 1967-02-10 | Mittel zur Steigerung der Lerngeschwindigkeit und zur Verlängerung der Beibehaltung des erlernten Verhaltens bei Tieren |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US3348999A (en, 2012) |
| BE (1) | BE693829A (en, 2012) |
| CH (1) | CH519847A (en, 2012) |
| DE (1) | DE1617287A1 (en, 2012) |
| ES (1) | ES336642A1 (en, 2012) |
| FR (1) | FR6264M (en, 2012) |
| GB (1) | GB1143061A (en, 2012) |
| GR (1) | GR33338B (en, 2012) |
| IL (1) | IL27353A (en, 2012) |
| NL (1) | NL6701761A (en, 2012) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3689644A (en) * | 1971-01-27 | 1972-09-05 | Abbott Lab | 2-imino-5-phenyl-4-oxazolidinone and a potentiating agent to treat parkinson{40 s disease |
| US3689643A (en) * | 1971-01-27 | 1972-09-05 | Abbott Lab | Combination of l-dopa, 2-imino-5-phenyl-4-oxazolidinone and an aluminum or alkaline earth metal salt or base used to treat parkinson{40 s disease |
| US4754047A (en) * | 1979-08-16 | 1988-06-28 | American Cyanamid Company | Phenylethanolamine derivatives and acid addition salts thereof for enhancing the growth rate of meat-producing animals and/or improving the efficiency of feed utilization thereby |
| US4522822A (en) * | 1980-12-22 | 1985-06-11 | American Cyanamid Company | Phenylethane derivatives and acid addition salts thereof for increasing lean meat deposition and/or improving lean meat to fat ratio in warm blooded animals |
| US4501751A (en) * | 1980-12-22 | 1985-02-26 | American Cyanamid Company | Phenylethanolamine derivatives and acid addition salts thereof for enhancing the growth rate of meat-producing animals and improving the efficiency of feed utilization thereby |
-
1966
- 1966-02-10 US US526345A patent/US3348999A/en not_active Expired - Lifetime
-
1967
- 1967-01-29 IL IL6727353A patent/IL27353A/xx unknown
- 1967-02-01 GR GR670133338A patent/GR33338B/el unknown
- 1967-02-06 NL NL6701761A patent/NL6701761A/xx unknown
- 1967-02-09 ES ES336642A patent/ES336642A1/es not_active Expired
- 1967-02-09 FR FR94275A patent/FR6264M/fr not_active Expired
- 1967-02-09 DE DE19671617287 patent/DE1617287A1/de active Pending
- 1967-02-09 BE BE693829D patent/BE693829A/xx unknown
- 1967-02-10 GB GB6607/67A patent/GB1143061A/en not_active Expired
- 1967-02-10 CH CH200167A patent/CH519847A/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR6264M (en, 2012) | 1968-08-26 |
| GB1143061A (en) | 1969-02-19 |
| US3348999A (en) | 1967-10-24 |
| IL27353A (en) | 1970-12-24 |
| DE1617287A1 (de) | 1971-03-25 |
| BE693829A (en, 2012) | 1967-08-09 |
| NL6701761A (en, 2012) | 1967-08-11 |
| ES336642A1 (es) | 1968-01-01 |
| GR33338B (el) | 1967-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69938179T2 (de) | Kombination von riluzol und levodopa zur behandlung von morbus parkinson | |
| CH519847A (de) | Mittel zur Steigerung der Lerngeschwindigkeit und zur Verlängerung der Beibehaltung des erlernten Verhaltens bei Tieren | |
| DE2429101A1 (de) | Das alpha-isomere des 2-chlor-9- eckige klammer auf 3'-(n'-2-hydroxyaethylpiperazinon)-propyliden eckige klammer zu -thioxanthens, dessen ester und saeureadditionssalze, verfahren zu deren herstellung und diese verbindungen enthaltende pharmazeutische mittel | |
| DE2621091A1 (de) | Arzneimittel zur behandlung von schweineruhr | |
| DE2253800A1 (de) | Alpha-amidinothioacetamidocephalosporansaeureverbindungen | |
| CH677608A5 (en, 2012) | ||
| DE2720288C2 (de) | Verwendung von Magnesiumsalzen zur Herstellung von Zubereitungen zur Behandlung von Nutztieren | |
| DE2831964C2 (en, 2012) | ||
| AT394946B (de) | Verfahren zur behandlung von an primaer durch treponema hyodysenteriae verursachter schweinedysenterie leidenden schweinen | |
| DE2631389A1 (de) | Pharmazeutisch wirksame behensaeureester von thioxanthenabkoemmlingen und verfahren zu deren herstellung sowie diese enthaltende pharmazeutische mittel | |
| DE1767540C2 (de) | Mittel zur Behandlung von Histomoniasis bei der Geflügelzucht | |
| DE2122278A1 (de) | Verfahren zum Haltbarmachen von Antiacidum-Zusammensetzungen | |
| DE2338059A1 (de) | Zusammensetzung fuer veterinaergebrauch zur bekaempfung von durchfall | |
| DE2259624C3 (de) | Antibakterielles Arzneimittel | |
| AT338553B (de) | Ratten- und mausebekampfungsmittel | |
| DE2262787C2 (de) | Antibakterielles Mittel | |
| AT233166B (de) | Verfahren zur Herstellung von Tetracyclin-Antibiotika enthaltenden Zusammensetzungen | |
| DE2448564A1 (de) | Mittel zur behandlung von fischkrankheiten und verfahren zu seiner herstellung | |
| AT319463B (de) | Röntgenkontrastmittel | |
| DE2818498C2 (en, 2012) | ||
| DE2508185A1 (de) | Zur selenmangeltherapie geeignete selen-derivate und deren zubereitungen | |
| DE2507565A1 (de) | Bekaempfung der laktischen acidose bei wiederkaeuern | |
| DE2350223A1 (de) | Ein in 4-stellung substituiertes 2-(3-pyridyl)thiazol enthaltendes pharmazeutisches mittel und seine verwendung | |
| AT209163B (de) | Beifuttermittel | |
| DE1617375C (de) | Arzneimittel zur Desensibilisierung gegenüber Penicillinen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |